The Fabrus-Senesco (SNTI) merger has been creating a lot of hype, primarily because of Dr. Phillip Frost's position as Chariman of Fabrus, along with chairing Teva Pharmaceuticals (NYSE:TEVA), Opko (NYSE:OPK) and Frost Gamma Investments Trust. He is a bit of a busy man. Frost has a long record of achievements, but the involvement of even a particularly green thumb should not be the sole criterion for making investment decisions, nor does it need to be in the case of Senesco.
Fabrus and Frost together bring two critical additions to Senesco. The first is, of course, money, which Senseco has been chronically short on. In one fell swoop, Senesco has gone from a peewee biotech with less...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|